KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Supernus Pharmaceuticals (SUPN) EBITDA Margin (2016 - 2025)

Historic EBITDA Margin for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to 31.35%.

  • Supernus Pharmaceuticals' EBITDA Margin fell 546000.0% to 31.35% in Q3 2025 from the same period last year, while for Sep 2025 it was 5.42%, marking a year-over-year decrease of 145100.0%. This contributed to the annual value of 12.34% for FY2024, which is 132100.0% up from last year.
  • Latest data reveals that Supernus Pharmaceuticals reported EBITDA Margin of 31.35% as of Q3 2025, which was down 546000.0% from 7.34% recorded in Q2 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' EBITDA Margin peaked at 24.14% during Q2 2021, and registered a low of 31.35% during Q3 2025.
  • Moreover, its 5-year median value for EBITDA Margin was 5.29% (2023), whereas its average is 5.19%.
  • Per our database at Business Quant, Supernus Pharmaceuticals' EBITDA Margin surged by 263800bps in 2024 and then tumbled by -546000bps in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' EBITDA Margin (Quarter) stood at 3.83% in 2021, then surged by 435bps to 20.52% in 2022, then crashed by -103bps to 0.61% in 2023, then soared by 2128bps to 12.29% in 2024, then plummeted by -355bps to 31.35% in 2025.
  • Its EBITDA Margin was 31.35% in Q3 2025, compared to 7.34% in Q2 2025 and 6.85% in Q1 2025.